Vima Therapeutics debuts with $60 million financing

Vima Therapeutics, a Cambridge, USA-based clinical-stage biotechnology company focused on oral therapies for movement disorders, has launched with a $60 million Series A financing.

The fundraiser was led by Atlas Venture, with participation from Access Industries and Canaan.

With a patient-focused approach, and highly experienced leadership team, Vima is advancing VIM0423, a potential first-in-class oral therapy for dystonia that targets the underlying cause in the central nervous system. The candidate is in a Phase I clinical trial, with plans to initiate Phase II by the fourth quarter of 2025.